ArticleAmerican journal of translational research2020
In vivo characterization of PD-L1 expression in breast cancer by immuno-PET with
Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy.Seminars in cancer biology · 2022Pooled it
- The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.Molecules (Basel, Switzerland) · 2021Pooled it
- Article
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Radiolabelling and preclinical characterisation of [European journal of nuclear medicine and molecular imaging · 2024Article
- Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities.Frontiers in medicine · 2024Review
- Optimal Indications of Radioimmunotherapy in Nuclear Medicine: A Mini-Review.Current radiopharmaceuticals · 2024Review
- Noninvasive PET imaging of tumor PD-L1 expression withAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Evaluation of Chelator-to-Antibody Ratio on Development ofInternational journal of molecular sciences · 2023Article
- Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications.EJNMMI research · 2023Review
- Review
- Design, Synthesis, and Biological Evaluation of a Small-Molecule PET Agent for Imaging PD-L1 Expression.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Imaging immunity in patients with cancer using positron emission tomography.NPJ precision oncology · 2022Review
- ImmunoPET: harnessing antibodies for imaging immune cells.Molecular imaging and biology · 2022Review
- Preclinical PET Imaging of Granzyme B Shows Promotion of Immunological Response Following Combination Paclitaxel and Immune Checkpoint Inhibition in Triple Negative Breast Cancer.Pharmaceutics · 2022Article
- Preclinical antibody-PET imaging of PD-L1.Frontiers in nuclear medicine · 2022Review
- ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.Frontiers in medicine · 2022Review
- Novel Tracers and Radionuclides in PET Imaging.Radiologic clinics of North America · 2021Review
- Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
Programmed death protein 1 and programmed death-ligand 1 (PD-1/PD-L1) have been widely studied as one of the most critical immune check-point pairs in the cancer microenvironment. In breast cancer (BrCa), the expression of PD-L1 is regarded as a determinant biomarker for patient stratification and prediction of inhibition response. Quantitative positron emission tomography (PET) imaging of PD-L1 expression in tumors using a therapeutic antibody in the clinic seems to be a promising approach that can complement conventional histopathological methods and overcome several issues, such as the tumor heterogeneities, sampling representativeness and clear differentiation of positive and negative results. In this study, we synthesized and evaluated
Indexed as
Identifiers
32509182PMC7270013W3033203115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.